Keywords: AstraZeneca, Vandetanib, Thyroid cancer, Kombiglyze, Zactima, Bristol-Myers Squibb, Type 2 diabetes

US FDA delays AstraZeneca’s vandetanib NDA for three months; combo diabetes drug Kombiglyze launched

Article | 10 January 2011

Print This

Anglo-Swedish drug major AstraZeneca (LSE: ANZ) announced last Friday that the US Food and Drug Administration has extended by three ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in